Immunotoxicity of pembrolizumab in patients with metastatic non-small cell lung cancer: A single-centre study
Background: Immunotherapy represents a new form of treatment that stimulates the immune system to destroy cancer cells. Pembrolizumab is a humanized monoclonal antibody that binds to the PD-1 programmed cell death receptor and blocks its interaction with the PD-L1 and PD-L2 ligands. The aim of this...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Institute of Oncology, Sremska Kamenica, Serbia
2024-01-01
|
| Colección: | Archive of Oncology |
| Materias: | |
| Acceso en línea: | https://scindeks-clanci.ceon.rs/data/pdf/0354-7310/2024/0354-73102401014S.pdf |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|